

Kidney Cancer GCOM 9 (day 1) minutes

Kidney Cancer update – committee meeting 9 (day 1) minutes

**Date:** 27/01/2025

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>		
Ana Semedo	Vice Chair	Present for items 1–8
Axel Bex	Urological Surgeon	Present for items 1–6
Janet Brown	Medical Oncologist	Present for items 2–8
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1–8
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1–5
John Connolly	Lay Member	Present for items 1–8
David Cullen	Urology Cancer Nurse	Present for items 1–8
Stuart Evans	Oncology Pharmacist	Present for items 1–8
Geraldine Fox	Lay Member	Present for items 1–8
David Mole	Nephrologist (co-opted member)	Present for items 1–8
Vishal Patil	Anaesthetist (co-opted member)	Present for items 1–8
Sandeep Singh Randhawa	General Practitioner	Present for items 1–8
Grant Stewart	Topic Adviser	Present for items 1–8
Maxine Tran	Urological Surgeon	Present for items 1–8
Sam Withey	Diagnostic Radiologist	Present for items 1–8

<b>In attendance NICE:</b>		
Marie Harrisingh	Topic Lead	Present for items 1–8
Callum Alexander	Coordinator (Observing)	Present for items 1–8
Sarah Boyce	Senior Technical Analyst	Present for items 1–8
Linda Chikelu	Coordinator (Observing)	Present for items 1–8
Lindsay Claxton	Health Economics Adviser	Present for items 1–8
Gareth Haman	Senior Guidance and Content Designer	Present for items 5–8
Jon Littler	Project Manager	Present for items 1–8
Lina Manounah	Technical Analyst (observing)	Present for items 1–4

## Kidney Cancer GCOM 9 (day 1) minutes

Agnesa Mehmeti	Technical Analyst	Present for items 1–8
Hannah Tebbs	Senior Health Economist	Present for items 1–8
Yuanyuan Zhang	Senior Health Economist	Present for items 1–8

<b>Apologies:</b>	
Adefisayo Abba-Abba	Technical Analyst, NICE
Lisa Browning	Histopathologist, Committee member
Victoria Carter	Implementation Support Manager, NICE
Danielle Conroy	Project Manager, NICE
Olivia Crane	Senior Technical Analyst, NICE
Fayiza Habeeb	Lead Nurse Practitioner, Committee member
James Hall	Senior Guidance and Content Designer, NICE
Ankit Rao	Medical Oncologist, Committee member
Baljit Singh	Chair, Committee member
Tze Min Wah	Interventional Radiologist, Committee member
Rose Woodward	Lay member, Committee member

### 1. Welcome, Introductions and DOIs

The Vice Chair, Ana Semedo (AS) welcomed the committee members and NICE attendees to day 1 of the 9th committee meeting for the NICE Kidney Cancer guideline.

AS informed attendees that apologies had been received as noted above. AS asked all committee members to verbally declare any new interests.

No new interests were declared and the minutes from committee 8 were checked and agreed to be an accurate record.

### 2. Revisit methods and evidence RQ5b (follow-up and monitoring for previously treated renal cell carcinoma):

- **Discussion around economic modelling**

The Chair introduced Yuanyuan Zhang (YZ) and Hannah Tebbs (HT), Senior Health Economists who presented the economic modelling plan to look at clinical and cost-effective follow-up strategies for monitoring long-term consequences of treatment and for early detection of recurrence or progression of the disease.

The committee had the opportunity to input and ask questions.

**3. RQ2b (core biopsy for suspected renal cell carcinoma):**

- **Introduction to diagnostic data**

The Chair introduced Agnesa Mehmeti (AM), Technical Analyst who gave an overview on diagnostic data which included measuring diagnostic accuracy, interpreting and decision-making using likelihood ratios before presenting the results from the evidence review.

**4. RQ2b (core biopsy for suspected renal cell carcinoma):**

- **Presentation of clinical evidence**
- **Presentation of HE evidence**
- **Committee discussion**
- **Health equality and inequality considerations**

The Chair introduced Lindsay Claxton (LC), Health Economics Adviser who along with AM presented the clinical and health economics evidence looking at the clinical and cost-effectiveness of core biopsy (compared with no biopsy) for suspected renal cell carcinoma.

The committee had the opportunity to discuss what was presented and ask questions and consider any equality and health inequality issues.

Drafting of recommendations was deferred until the results of the economic modelling are available.

AS thanked the committee for their input.

**5. RQ5a (active surveillance for small / suspected benign renal lesions - method, duration and frequency):**

- **Revisiting clinical evidence and discussions**
- **Revising recommendations**

The Chair introduced Marie Harrisingh (MH), Topic Lead who revisited the clinical evidence and recommendations drafted at previous meetings for follow-up and monitoring of untreated renal masses.

The NICE team had questions which required further committee input.

The committee discussed what was presented and suggested revisions to the draft recommendations and research recommendations.

AS thanked the committee for their input.

**6. RQ5a continued**

Continuation of item above.

**7. Revisiting recommendations and review protocol questions:**

- **Protocol queries for review 5ci on genetic testing**

The Chair introduced Sarah Boyce (SB), Senior Technical Analyst who presented the review protocol for genetic assessment for renal cell carcinoma for further consideration.

The committee had the opportunity to review the questions in the scope, consider existing NHS England testing criteria and offer their expert input after group discussion.

AS thanked the committee for their input.

**8. Next steps and AOB**

AS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AS brought the meeting to a close.

**Date of next meeting:** 07/02/2025

**Location of next meeting:** Virtual and NICE, 2 Redman Place, London